Loading company…
Ovid Therapeutics is a biotechnology company developing small molecule therapies for neurological disorders, particularly epilepsy.
Ovid Therapeutics develops targeted small molecule therapies for neurological diseases, particularly epilepsies and cerebral cavernous malformations, aiming to reduce seizure frequency and improve safety. Founded in 2014 and based in New York, US, the company is at the Series B stage. It raised USD 50.00 mn in a 2020 private placement and follow-on round, and its CEO is Jeremy Levin.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in